Biomarkers in systemic lupus erythematosus (Q35882067)

10 August 2017

1 reference

title

Biomarkers in systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

10 August 2017

0 references

0 references

author name string

Gabor G Illei

series ordinal

1

1 reference

PubMed ID

15355751

10 August 2017

Peter E Lipsky

series ordinal

2

1 reference

10 August 2017

1 October 2004

1 reference

Current Rheumatology Reports

10 August 2017

1 reference

10 August 2017

6

1 reference

10 August 2017

382-390

1 reference

10 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-004-0013-4

10 August 2017

0 references

cites work

Surrogate end points in clinical trials: are we being misled?

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-004-0013-4

Overview of biomarkers and surrogate endpoints in drug development

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11926-004-0013-4

Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus

21 January 2018

1 reference

12 December 2020

The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation

1 reference

12 December 2020

The genetics of systemic lupus erythematosus: putting the pieces together

1 reference

12 December 2020

Association of mannose-binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients.

1 reference

12 December 2020

Role of the Fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis

1 reference

12 December 2020

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

1 reference

12 December 2020

Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death

1 reference

12 December 2020

Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus

1 reference

12 December 2020

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies

1 reference

12 December 2020

Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus

1 reference

12 December 2020

Laboratory tests as predictors of flares in systemic lupus erythematosus: comment on the article by Esdaile et al

1 reference

12 December 2020

Prevention of relapses in systemic lupus erythematosus

1 reference

12 December 2020

Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment?

1 reference

12 December 2020

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood

1 reference

12 December 2020

Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility

1 reference

12 December 2020

Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study

1 reference

12 December 2020

Soluble interleukin-2 receptor levels in lupus nephritis

1 reference

12 December 2020

Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study

1 reference

12 December 2020

Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail

1 reference

12 December 2020

Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability

1 reference

12 December 2020

Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms

1 reference

12 December 2020

Interleukin-1 receptor antagonist gene polymorphism in chinese patients with systemic lupus erythematosus

1 reference

12 December 2020

Biomarkers in systemic lupus erythematosus: II. Markers of disease activity

1 reference

12 December 2020

Following the disease course in systemic lupus erythematosus: are serologic variables of any use?

1 reference

12 December 2020

The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus

1 reference

12 December 2020

Development of anti-dsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus

1 reference

12 December 2020

Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis

1 reference

12 December 2020

Serum levels of interferons in patients with systemic lupus erythematosus

1 reference

12 December 2020

Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy

1 reference

12 December 2020

Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus.

1 reference

12 December 2020

Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus

1 reference

12 December 2020

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

1 reference

12 December 2020

Laboratory abnormalities and systemic lupus erythematosus flare: comment on the article by Esdaile et al

1 reference

12 December 2020

Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis

1 reference

12 December 2020

Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers.

1 reference

12 December 2020

Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies?

1 reference

12 December 2020

Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus

1 reference

12 December 2020

Association of the interferon-gamma receptor variant (Val14Met) with systemic lupus erythematosus

1 reference

12 December 2020

Genetic linkage and association of Fc? receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus

1 reference

12 December 2020

Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus

1 reference

12 December 2020

Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus

1 reference

12 December 2020

A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans

1 reference

12 December 2020

Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus

1 reference

12 December 2020

Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course

1 reference

12 December 2020

Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases

1 reference

12 December 2020

Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity

1 reference

12 December 2020

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

1 reference

12 December 2020

Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus

1 reference

12 December 2020

The FcγRIIIA-F158 allele is a risk factor for the development of lupus nephritis: A meta-analysis

1 reference

12 December 2020

Relationship between lupus nephritis activity and the serum level of soluble VCAM-1.

1 reference

12 December 2020

Cytokines and adhesion molecules in renal vasculitis and lupus nephritis.

1 reference

12 December 2020

Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus.

1 reference

12 December 2020

The contribution of clinical pharmacology surrogates and models to drug development--a critical appraisal

1 reference

12 December 2020

10.1007/S11926-004-0013-4

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15355751